South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Fountain Therapeutics is raising $15,864,168.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Greene played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Fountain Therapeutics
Fountain Therapeutics is building a pipeline of therapeutics to treat age-related diseases by reversing cellular age. The company has combined the expertise of leaders in aging research and computation to build an AI-driven platform that extracts previously hidden cellular features to measure aging with remarkable precision. Fountain is currently screening a large diversity of drug compounds, including small molecules and biologics, to identify novel drugs that specifically reverse the age of cells for the development of therapeutics to treat age-related diseases. Fountain is comprised of an exceptional growing team of scientists, engineers, physicians, drug hunters and developers, and entrepreneurs originating from top academic institutions, research laboratories and biotech companies in the world. The team is united by the common goal of building a new way forward to decouple aging from disease and improve the quality of life for our aging population.

To learn more about Fountain Therapeutics, visit http://www.fountaintx.com/

Contact:
William Greene, Chief Executive Officer
650-856-1971
https://www.linkedin.com/in/william-greene-83846/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved